Cutler J A
Circulation. 1983 Jun;67(6 Pt 2):I62-5.
Ten randomized clinical trials of beta-blocking drugs in secondary prevention of coronary heart disease are reviewed. The six trials of long-term treatment involving three drugs have completed recruitment; the results should be reported during the next few years. In addition to the possibility of confirming the positive results from other trials, the findings may provide further information on the timing of treatment initiation and the mechanism of benefit. Three of the four trials concerned with the efficacy of beta blockers in the early acute phase of myocardial infarction are still recruiting. Two of these (the Prehospital Myocardial Infarction Study and the International Study of Infarct Survival) are large trials aiming to determine the effect on mortality from all causes. The third (Multicenter Investigation of the Limitation of Infarct Size) has infarct size as the primary end point, as does the one trial with completed follow-up (Belfast), whose preliminary findings indicate no effect on threatened infarction.
本文回顾了十项关于β受体阻滞剂在冠心病二级预防中的随机临床试验。六项涉及三种药物的长期治疗试验已完成招募；结果应在未来几年内公布。除了有可能证实其他试验的阳性结果外，这些发现可能会提供有关治疗开始时间和获益机制的更多信息。四项关于β受体阻滞剂在心肌梗死早期急性期疗效的试验中有三项仍在招募患者。其中两项试验（院前心肌梗死研究和国际心肌梗死存活研究）是大型试验，旨在确定对全因死亡率的影响。第三项试验（梗死面积限制多中心研究）以梗死面积作为主要终点，已完成随访的一项试验（贝尔法斯特试验）也是如此，其初步结果表明对濒临梗死无影响。
